Bibliography
- Gross CJ, Kramer JA. The role of investigative molecular toxicology in early stage drug development. Expert Opin Drug Saf 2003;2:147-59
- Greaves P, Williams A, Eve M. First dose of potential new medicines to humans: how animals help. Nat Rev Drug Discov 2004;3:226-36
- Frantz S, Smith A. New drug approvals for 2002. Nat Rev Drug Discov 2003;2:95-6
- Dimasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003;22:151-85
- US Food and Drug Administration. Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. Available from: URL: www.fda.gov/oc/initiatives/criticalpath/whitepaper.html [Last accessed 4 February 2008]
- Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67
- Mutlib AE, Gerson RJ, Meunier PC, et al. The species-dependent metabolism of efavirenz produces a nephrotoxic glutathione conjugate in rats. Toxicol Appl Pharmacol 2000;169:102-13
- Wu KM, Farrelly JG. Preclinical development of new drugs that enhance thyroid hormone metabolism and clearance: inadequacy of using rats as an animal model for predicting human risks in an IND and NDA. Am J Ther 2006;13:141-4
- Cohen SM, Lawson TA. Rodent bladder tumors do not always predict for humans. Cancer Lett 1995;93:9-16
- Sasseville VG, Lane JH, Kadambi VJ, et al. Testing paradigm for prediction of development-limiting barriers and human drug toxicity. Chem Biol Interact 2004;150:9-25
- Kramer JA, Sagartz JE, Morrsi DL. The application of discovery toxicology and pathology towards the design of safer pharmaceutical lead candidates. Nat Rev Drug Discov 2007;6:636-49
- Searfoss GH, Jordan WH, Calligaro DO, et al. Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor. J Biol Chem 2003;278:46107-16
- Sawada H, Takami K, Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol Sci 2005;83:282-92
- Moyle G. Mitochondrial toxicity: myths and facts. J HIV Ther 2004;9:45-7
- Hutzler M, Messing DM, Wienkers LC. Predicting drug-drug interactions in drug discovery: where are we now and where are we going? Curr Opin Drug Discov Dev 2005;8:51-8
- Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007;7:332-44
- Doss GA, Baillie TA. Addressing metabolic activation as an integral component of drug design. Drug Metab Rev 2006;38:641-9
- Critical Path Institute, Tucson, AZ. Available from: URL: www.c-path.org [Last accessed 4 February 2008]